Kardiocentrum Všeobecné fakultní nemocnice a 1. LF UK v Praze


Peripheral Arterial Disease - antiplatelet therapy

Debora Karetová

Ind Dept for Cardiology and Angiology General Faculty Hospital Ist Medical Faculty, Charles University, Prague, Czech Rep.


> CARDIONALE PRAGUE 2010

Documented Presence of PAD



- 1. Selvin E, Erlinger TP. NHANES. *Circulation.* 2004;110:738-743.
- 2. Criqui MH, et al. *Circulation.* 1985;71:510-515.
- 3. Diehm C, et al. Atherosclerosis. 2004;172:95–105.
- 4. Meijer WT, et al. Arterioscler Thromb Vasc Biol. 1998;18:185-192.
- 5. Hirsch AT, et al. *JAMA*. 2001;286:1317-1324.


Prevalence of PAD Increases With Age




Adapted from Golomb BA, et al. In: Creager MA, ed. *Management of Peripheral Arterial Disease: Medical, Surgical and Interventional Aspects*; 2000:1-18. Meijer WT, et al. *Arterioscler Thromb Vasc Biol*. 1998;18:185-192. Criqui MH, et al. *Circulation*. 1985;71:510-515.

Risk Factors for PAD

PragueAngio 2008



Risk Factors for PAD



TASC II Working Group


SMOKER

occlusions of pelvic arteries

DIABETIC

occlusion a.fibularis a.tib.post.


Overlap Between PAD, CAD, and CVD



Patients with one manifestation often have coexistent disease in other vascular beds.

Bhatt DL, et al. REACH Investigation. Presented at: American College of Cardiology Annual Scientific Session; March 8, 2005; Orlando, FL. Abstract 1127-96.

Diagnostic Algorithm for PAD



The 5-year all-cause mortality rates are as high as 30% in patients with PAD,

PAD pts are 6 times more likely to die from CV disease within 10 yrs than pts without PAD



Prevention of MI, stroke & death

Management of PAD

Improvement of function and QoL


Protection of feet – limb salvage

Treatment of All PAD Pts


Exercise programme


Risk factor normalization:


- Immediate smoking cessation
- Treatment of hypertension
- Treatment of dyslipidemia to target levels
- Treatment of diabetes mellitus to $HbA_{1c} < 7\%$ (4,5%)



Antiplatelet therapy








Efficacy of Antiplatelet therapy, ACE-I, Statins in PAD

No. of patients in subgroup



APTC Antiplatelet Trialists' Collaboration BMJ 1994; 308:81-106 CAPRIE Steering Committee Lancet 1996; 348: 1329-1339 HOPE Study Investigators N Engl J Med 2000; 342:145-153 HPS Collaborative group Lancet; 2002; 360:7-22

Antithrombotic Trialists' Collaboration: PAD

- 42 clinical trials
- 9,214 patients with PAD
- 23% reduction of serious adverse vascular events (P=.004)
- Benefits similar among PAD subtypes (intermittent claudication, peripheral grafting, and peripheral angioplasty)

Antithrombotic Trialist's Collaboration. BMJ. 2002;324:71-86.

Antithrombotic Trialists' Collaboration Risk of Vascular Events in High-Risk Patients

Risk Category (number of trials)	Patients with Event (%)		Risk versus Control				
	APT	Control	F	Reduced	Incr	eased 🕨	
Intermittent claudication (N=26)	6.4	7.9					
Peripheral grafting (N=12)	5.4	6.5					
Peripheral angioplasty (N=4)	2.5	3.6	_				
All PAD trials (N=42)) 5.8	7.1		\diamond		N=97	706
			0.0	0.5	1.0	1.5	2.0

APT=antiplatelet therapy with aspirin, clopidogrel, dipyridamide, or a glycoprotein IIb/IIIa antagonist

Antithrombotic Trialists' Collaboration. BMJ. 2002:324:71-86.

Is really the acetylsalicylic acid so beneficial drug for the patients with PAD ?

Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease: A Meta-analysis of Randomized Trials

Jeffrey S. Berger; Mori J. Krantz; John M. Kittelson; et al.

JAMA. 2009;301(18):1909-1919 (doi:10.1001/jama.2009.623)

- 18 trials involving 5 269 pts (1966-2008)
- CV events in 8,9% taking ASA and by 11% in the control group –nonsignificant 12% RR
- Reduction of nonfatal stroke but not associated with significant reduction in all-cause or cardiovascular mortality, MI
- 3 019 taking ASA alone (7 trials)

 the same results

Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease: A Meta-analysis of Randomized Trials

Jeffrey S. Berger; Mori J. Krantz; John M. Kittelson; et al.

JAMA. 2009;301(18):1909-1919 (doi:10.1001/jama.2009.623)

events with a benefit of less than 15%

18 trials involving 5 269 pts (1966-2008)

Limitations:

- no evaluation of peripheral vascular events - the analysis is underpowered to detect a difference in primary outcome of less than 25% Aspirin is efficacious in reducing vascular


ated

in

60% of the data come from: POPADAD trial, VA-**Cooperative trial**

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease

Jill Belch, professor of vascular medicine,¹ Angus MacCuish, consultant diabetologist,² Iain Campbell, professor of diabetic medicine,³ Stuart Cobbe, Walton professor of cardiology,⁴ Roy Taylor, professor of medicine and metabolism,⁵ Robin Prescott, professor of health technology assessment,⁸ Robert Lee, research associate,⁸ Jean Bancroft, senior research nurse,¹ Shirley MacEwan, honorary senior research fellow,¹ James Shepherd, professor of pathological biochemistry,⁶ Peter Macfarlane, professor of




- ASA was not effective in the primary of CV events in pts with asymptomatic PAD
- Antioxidants showed no benefit as well

BMJ 2008, 337: 1840

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease

Jill Belch, professor of vascular medicine,¹ Angus MacCuish, consultant diabetologist,² Iain Campbell, professor of diabetic medicine,³ Stuart Cobbe, Walton professor of cardiology,⁴ Roy Taylor, professor of medicine and metabolism,⁵ Robin Prescott, professor of health technology assessment,⁸ Robert Lee, research associate,⁸ Jean Bancroft, senior research nurse,¹ Shirley MacEwan, honorary senior research fellow,¹ James Shepherd, professor of pathological biochemistry,⁶ Peter Macfarlane, professor of



BMJ 2008, 337: 1840

Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index


A Randomized Controlled Trial

F. Gerald R. Fowkes, FRCPE Jacqueline F. Price, MD Marlene C. W. Stewart, PhD Isabella Butcher, PhD Gillian C. Leng, MD Alistair C. H. Pell, MD Peter A. G. Sandercock, DM Keith A. A. Fox, FRCP Gordon D. O. Lowe, DSc Gordon D. Murray, PhD for the Aspirin for Asymptomatic Atherosclerosis Trialists

AAA trial

Aspirin for Asymptomatic Atherosclerosis

 among participants without clinical CV disease, identified with a low ABI based on screening a general population, the administration of ASA did not reduce vascular events



Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index

A Randomized Controlled Trial


F. Gerald R. Fowkes, FRCPE Jacqueline F. Price, MD Marlene C. W. Stewart, PhD Isabella Butcher, PhD Gillian C. Leng, MD Alistair C. H. Pell, MD Peter A. G. Sandercock, DM Keith A. A. Fox, FRCP Gordon D. O. Lowe, DSc Gordon D. Murray, PhD for the

AAA trial

Aspirin for Asymptomatic Atherosclerosis

Monthered and State of events lower than expected
 Imited power of the study
 Imited coated acetylsalicylic acid

on screening a general population, the administration of ASA did not reduce vascular events



Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial

Critical Leg Ischaemia Prevention Study (CLIPS) Group*

- Prevention of vascular events by aspirin amongst 366 pts with stage I-II (ABI < 0,85)
- Randomized, placebo-controlled
- 4 treatment groups: aspirin/vitE+C+betacarotene/both/neither
- 7/185 aspirin X 20/181 placebo suffered major CV event – reduction of 64%, 5 vs 8 cases of critical limb ischemia

Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial


Critical Leg Ischaemia Prevention Study (CLIPS) Group*

- Prevention of vascular events by aspirin among Small study, small No of events ⁵)
- Rando Antioxidants no effect
- 4 treatment groups: aspirin/vitE+C+betacarotene/both/neither
- 7/185 aspirin X 20/181 placebo suffered CVevent – reduction

Clopidogrel

Clopidogrel is a prodrug -> Metabolism through the cytochrome P450 enzyme system


Active metabolite binds to platelet P2Y12 receptor and irreversibly blocks platelet activation by ADP



Simon et al., *NEJM* 2009;360:363-375.


CAPRIE Study

Efficacy of Clopidogrel in Primary Analysis of MI, Ischemic Stroke, or Vascular Death



CAPRIE Steering Committee Lancet 1996; 348: 1329-1339


CAPRIE Study Outcome by Subgroup



CAPRIE Steering Committee Lancet 1996; 348: 1329-1339

CHARISMA

Primary Endpoint (MI/Stroke/CV Death) in Patients with Previous MI, IS, or PAD*



Bhatt DL. Presented at ACC 2006.



- PAD is a marker of atherosclerosis in the coronary and cerebral arteries
- PAD is often underestimated and underdiagnosed, and requires propper diagnosis
- Antiplatelet therapy reduces the risk of myocardial infarction, stroke and vascular death in patients with peripheral arterial disease, including patients with a history of angioplasty or bypass surgery^{1,2}
- Most of the evidence with antiplatelet therapy in PAD is from ASA and ADP-receptor antagonists including clopidogrel^{1,3}
- An ADP-receptor antagonist improves the long-term peripheral patency after revascularization procedures²

1. Robless P *et al. Br J Surg* 2001; 88: 787–800**. 2** Becquemin JP. *N Engl J Med* 1997; 337: 1726–31. 3. Girolami B *et al. Eur J Vasc Endovasc Surg* 2000; 19: 370–80. 4. Bhatt DL *et al. Am Heart J* 2000; 140: 67–73.



- The effect of aspirin in patients with PAD caused risk reduction of 20%, only 12% in primary prevention trials
- The benefit of aspirin in PAD pts is clear in reduction of nonfatal stroke
- Clopidogrel provides increased benefit over aspirin for secondary prevention in atherothrombotic patients, including those with diagnosed PAD
- Dual antiplatelet therapy may be beneficial in pts with extensive atherosclerotic disease

